TT-01 ADC

Antibody Drug Conjugate

In the field of cancer treatment, biopharmaceutical companies are continually seeking new strategies that are safer and more effective. Antibody-drug conjugates (ADCs) have emerged as one of the most promising precision therapies, combining the targeting power of antibodies with the potent cytotoxicity of small-molecule drugs. Acting like a "smart missile," ADCs are designed to precisely attack cancer cells while sparing healthy tissue.

Each ADC consists of three key components: an antibody, a linker, and a cytotoxic payload. The antibody selectively binds to antigens on the surface of cancer cells; once internalized, the linker releases the payload, which disrupts critical cellular functions or damages DNA, leading to cell death. The design and selection of the antibody are critical to ADC performance, requiring high specificity, strong binding affinity, and robust in vivo stability to ensure efficient drug delivery.

Compared to traditional chemotherapy, ADCs offer significant advantages: reduced off-target toxicity, the ability to overcome drug resistance, and a modular design that enables rapid adaptation to new targets and indications. With several ADCs already approved and many more advancing through clinical trials, the demand for next-generation ADCs with improved selectivity and safety profiles continues to grow. At Topmunnity Therapeutics, we are leveraging technological innovation, strategic partnerships, and a flexible development platform to build a strong and differentiated position in the ADC space.

TT-01 ADC is an antibody-drug conjugate (ADC) targeting a validated oncology target, engineered to deliver superior therapeutic performance through enhanced internalization. Compared to existing ADCs against the same antigen, TT-01 ADC has demonstrated remarkedly higher rates of internalization into cancer cells, enabling more efficient payload delivery and maximizing cytotoxic effects at the tumor site.

This improved internalization profile positions TT-01 ADC as a promising candidate to overcome common limitations associated with current ADCs targeting the same antigen, such as suboptimal cellular uptake and limited therapeutic efficacy. By ensuring that a greater proportion of payload molecules reach the intracellular environment, TT-01 aims to achieve deeper tumor cell killing while maintaining favorable safety margins. TT-01 ADC is being developed as a best-in-class drug targeting the specific target.

TT-01 has shown encouraging results in preclinical studies and is advancing toward IND-enabling development.